Alpha-synuclein detection using beads
A method is provided for determining the presence of soluble, misfolded α-synuclein protein in a biological sample. The method comprises contacting the biological sample with a pre-incubation mixture, the pre-incubation mixture comprising: a monomeric α-synuclein protein; a buffer composition; a salt; and an indicator, to form an incubation mixture. An incubation cycle is conducted on the incubation mixture in the presence of either a silicon nitride bead or a borosilicate glass bead having a diameter of from about 1 mm to about 5 mm. The method further comprises determining if a detectable amount of misfolded α-synuclein aggregate is present in the biological sample.
1. An in vitro method for detecting the presence of alpha-synuclein (α-syn) aggregate in a biological sample, the method comprising:
(A) providing a biological sample;
(B) providing a pre-incubation mixture, the pre-incubation mixture comprising:
(1) a monomeric α-syn protein;
(2) a buffer composition;
(3) a salt;
(4) a fluorescent protein aggregation indicator; and
(5) one or more Si 3 N 4 beads having a diameter of 1 mm to 5 mm;
(C) combining the biological sample and the pre-incubation mixture to form an incubation mixture;
(D) incubating and agitating the incubation mixture to form an incubated mixture;
(E) illuminating the incubated mixture with a wavelength of light that excites the fluorescent protein aggregation indicator; and
(F) determining a level of fluorescence during incubation,
wherein an increase in the level of fluorescence during incubation indicates the presence of α-syn aggregate in the biological sample.
2. The method of claim 1 , wherein the Si 3 N 4 bead has a diameter of 2.3 mm to 5 mm.
3. The method of claim 1 , wherein the Si 3 N 4 bead comprises a coating of bovine serum albumin (BSA).
4. The method of claim 1 , wherein the monomeric α-syn protein is present in a concentration of from 10 μM±10% to 30 μM±10%.
5. The method of claim 1 , wherein the monomeric α-syn protein comprises SEQ ID NO. 2.
6. The method of claim 1 , wherein the buffer composition comprises PIPES.
7. The method of claim 1 , wherein the salt comprises NaCl.
8. The method of claim 1 , wherein the salt comprises NaCl in a concentration between 500±10% mM to 700±10% mM.
9. The method of claim 1 , wherein the fluorescent protein aggregation indicator comprises thioflavin T (ThT).
10. The method of claim 1 , wherein the pre-incubation mixture further comprises sarkosyl.
11. The method of claim 1 , wherein the increase in the level of fluorescence is an increase in the level of fluorescence of the incubated mixture at maximum fluorescence of at least two times the standard deviation of the fluorescence of the incubated mixture at maximum fluorescence compared to the level of fluorescence of the incubated mixture during a lag phase.
12. The method of claim 1 , wherein detecting the presence of α-syn aggregate in the biological sample indicates the presence of a protein misfolding disorder.
13. The method of claim 12 , wherein the protein misfolding disorder comprises at least one of: Parkinson's disease, Lewy body dementia, and multiple system atrophy.
14. An in vitro method for detecting the presence of alpha-synuclein (α-syn) aggregate in a biological sample, the method comprising:
(A) providing a biological sample
(B) providing a pre-incubation mixture, the pre-incubation mixture comprising:
(1) a monomeric α-syn protein;
(2) a buffer composition;
(3) a salt;
(4) a fluorescent protein aggregation indicator; and
(5) a borosilicate glass bead having a diameter greater than 2.3 mm;
(C) combining the biological sample and the pre-incubation mixture to form an incubation mixture;
(D) incubating and agitating the incubation mixture to form an incubated mixture;
(E) illuminating the incubated mixture with a wavelength of light that excites the protein aggregation indicator; and
(F) determining a level of fluorescence during incubation, wherein an increase in the level of fluorescence during incubation indicates the presence of α-syn aggregate in the biological sample.
15. The method of claim 14 , wherein:
(i) the monomeric α-syn protein is present in a concentration of from 10 μM±10% to 30 μM±10%;
(ii) the buffer composition comprises PIPES and has a pH of from 6.2±10% to 6.5±10%;
(iii) the salt comprises NaCl in a concentration of from 500±10% mM to 700 mM±10%;
(iv) the borosilicate glass bead has a diameter of 2.45 mm±10%;
(v) the fluorescent protein aggregation indicator comprises thioflavin T (ThT) in a concentration of from 5 μM to 10 μM; and
(vi) the detection comprises measuring ThT fluorescence.
16. The method of claim 14 , wherein the pre-incubation mixture further comprises sarkosyl.
17. The method of claim 14 , wherein the increase in the level of fluorescence is an increase in the level of fluorescence of the incubated mixture at maximum fluorescence of at least two times the standard deviation of the fluorescence of the incubated mixture at maximum fluorescence compared to the level of fluorescence of the incubated mixture during a lag phase.
18. The method of claim 14 , wherein detecting the presence of α-syn aggregate in the biological sample indicates the presence of a protein misfolding disorder.
19. The method of claim 18 , wherein the protein misfolding disorder comprises at least one of: Parkinson's disease, Lewy body dementia, and multiple system atrophy.